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Abstract 
Autoimmune thyroid disease (AITD) is 
characterised by the development of thyroid 
autoantibodies, mainly anti-thyroid peroxidase 
antibodies, anti-thyroglobulin antibodies (primarily 
found in Hashimoto’s thyroiditis [HT]) and thyroid 
stimulating hormone receptor antibodies 
(predominate in Graves’ disease [GD]).  While 
genetic factors provide 70 to 80% of the risk for the 
development of thyroid autoimmunity (TAI), 
environmental factors contribute about 20 to 30% to 
the immunopathogenesis of AITD. Such 
environmental factors include smoking (predisposes 
to GD but protects against HT), alcohol (moderate 
consumption protects against both HT and GD), 
stress (predisposes to GD) and iodine (possibly 
increases risk of AITD).  Low selenium and vitamin 
D levels might increase the risk of TAI, although 
data remains indeterminate and selenium 
supplementation did not always improve TAI in 
clinical studies.  Additionally, certain drugs, toxic 
chemicals, infections, birth in winter and autumn 
and radiation exposure have also been implicated in 
the development of TAI.  Preventive interventions 
to decrease the risk of AITD are limited and not 
always feasible, though personal and public health 
interventions might help with smoking and iodine 
exposure. 
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Introduction 
Autoimmune thyroid disease (AITD) is a 
multifactorial disorder characterised by the 
development of autoantibodies against particular 
thyroid antigens in genetically predisposed 
individuals, facilitated by the exposure to particular 
environmental factors. Anti-thyroid peroxidase 
antibodies (TPO-Abs), anti-thyroglobulin 
antibodies (Tg-Abs) and thyroid stimulating 
hormone receptor antibodies (TSH-R Abs), are the 
main autoantibodies occurring in  AITD.1  While 
TPO- and Tg-Abs are mainly associated with 
Hashimoto’s thyroiditis (HT), TSH-R Abs are the 
main anti-thyroid antibodies found in Graves’ 
disease (GD).1-2 Thyroid autoimmunity (TAI) in the 
absence of clinical autoimmune disease is identified 
by the presence of these antibodies.2  
Primary hypothyroidism caused by HT forms 
the bulk of clinical disease. Its incidence rises with 
increasing age and is more common in iodine 
sufficient populations.2 The incidence rates of 
autoimmune hypothyroidism are 80/100,000/year in 
males and 350/100,000/year in females.  On the 
other hand, the incidence rates of autoimmune 
hyperthyroidism are 8/100,000/year in males and 
80/100,000/year in females.3 In the third National 
Health and Nutrition Examination Survey, TPO-
Abs were observed to be three times less prevalent 
in African blacks than in white Caucasians.4  
It has been observed in twin studies that genetic 
factors, including polymorphisms in major 
histocompatibility genes (human leukocyte 
antigen), thyroid specific genes (e.g. TSH-R and 
thyroglobulin genes) and immunoregulatory genes 
(such as the cytotoxic T lymphocyte antigen-4 
gene), provide a contribution of about 79% to the 
development of GD.5-6  Similarly, genetic factors 
account for about 73% of the risk to develop TPO- 
and/or Tg-Abs.7 Thus, environmental factors 
contribute about 20 to 30% to the 
immunopathogenesis of AITD.6  
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Existential Factors 
Existential factors include age, female sex and 
parity.6 In epidemiological studies, prevalence of 
thyroid antibodies was noted to increase with age2, 4 
(although a peak of antibody positivity at around 45 
to 55 years is demonstrated in a few studies).2 GD 
incidence was seen to peak at an age between 20 
and 49 years in two studies, between 60 and 69 
years in Malmö Sweden, while it increased with age 
in Iceland.8 AITD has a strong female 
preponderance, which may in part be explained by 
skewed X chromosome inactivation,1 and in part by 
hormonal influences, as oestrogen appears to favour 
a T-helper 2 immune response, where antibody 
production is increased through activation of B-
lymphocytes.9
Pregnancy is characterised by 
immunosuppression to protect the foetus.  However, 
this amelioration in immunity disappears in the 
post-partum period, often leading to the 
onset/exacerbation of existing AITD.10 In the 
prospective Amsterdam AITD cohort study, there 
were more hypothyroid cases in the postpartum 
period, while hyperthyroid cases were more 
frequent during pregnancy.11 The reason for an 
association between parity and AITD might be 
explained by foetal microchimerism, since foetal 
cells have been identified in the blood and thyroid 
tissue of women with HT and GD. This might 
trigger a graft-versus-host maternal immune 
response, leading to autoimmune diseases.12 
However, other population-based studies contradict 
this hypothesis, where no association was found 
between previous pregnancies, parity or abortion 
and thyroid antibodies.13-14  
 Environmental Factors 
1. Smoking
Smoking is a well-known risk factor for GD. A
meta-analysis showed an odds ratio (OR) of 3.30 
(95% confidence intervals [CI], 2.09, 5.22) for GD, 
with an even greater OR of 4.40 (95% CI, 2.88, 
6.73) for Graves ophthalmopathy in current 
smokers when compared to never smokers. This 
effect is more marked in women and appears to be 
dose dependent.  However, this risk is abolished a 
few years after smoking cessation, resulting in an 
insignificant OR of 1.41 (95% CI, 0.77, 2.58) for 
GD in ex-smokers compared to never smokers.15   
On the other hand, current smoking protects 
against autoimmune hypothyroidism in a dose-
dependent manner.  This has been shown in several 
studies, including a population-based study by 
Pederson et al, where smoking was negatively 
associated with the presence of Tg-Abs more than 
TPO-Abs.16 In contrast, discontinuation of smoking 
increased the risk for developing both TPO- and/or 
Tg-Abs,17 with a 6-fold increase in overt 
autoimmune hypothyroidism in the first 2 years 
following smoking cessation, although this 
increased risk was transient (DanThyr study).18   
2. Alcohol
Alcohol has been shown to protect against
autoimmune hypothyroidism. In a population-based 
case-control study carried out in Denmark, 
moderate alcohol consumption (11–20 units/week) 
was mostly protective, irrespective of gender, 
smoking and type of alcohol consumed.19 Moderate 
alcohol consumption (compared to 
abstinence/abuse) also protected against the 
development of GD with hyperthyroidism, thus 
indicating a dose-dependent relationship.20  
3. Stress
Stress is known to be a triggering factor in the
pathogenesis of GD, however, its effect on HT has 
been barely researched.6 In a five-year follow-up 
prospective study, stress was not found to be 
associated with the development of TPO-Abs or 
with the development of hypo- or hyperthyroidism.  
Hypothyroid cases were in fact found to suffer from 
a less depressed mood than controls at the point of 
diagnosis, and thus the authors concluded that stress 
is not implicated in the development of AITD.21   
However, in a population-based case-control 
study, stress and negative life events within the 
previous 12 months were found to be associated 
with the onset of GD.22 Another case-control 
retrospective study confirmed a correlation between 
stressful life events (SLE) and the onset of GD, 
while no association was found between SLE and 
the onset of toxic nodular goitre, confirming that 
stress precipitates autoimmune rather than non-
autoimmune hyperthyroidism.23 Moreover, the 
prognosis of GD treated with antithyroid drugs 
appears to be worse, with higher relapse rates and 
TSH-R Ab titres following treatment withdrawal in 
individuals who suffer from mental disorders and 
significant stress.24   
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4. Selenium
Selenoproteins, mainly glutathione peroxidases,
iodothyronine deiodinases and thioredoxin 
reductases are important enzymes involved with 
thyroid hormone metabolism, regulation of the 
redox state as well as protection of the thyroid gland 
from oxidative damage.1 A recent large population-
based study carried out in China demonstrated a 
higher incidence of autoimmune thyroiditis in 
individuals with low selenium.25 Low selenium 
levels were also noted to be associated with AITD, 
especially GD, in another population-based study 
carried out in Denmark.26   
However, the results of clinical trials testing the 
effect of selenium supplementation on TAI are 
equivocal.1 A Cochrane database systematic review 
concluded that further randomized placebo-
controlled trials are required to assess the effect of 
selenium supplementation on HT as the evidence so 
far is incomplete.27   
5. Vitamin D
Although Vitamin D deficiency is associated
with various autoimmune diseases including type 1 
diabetes (T1D) and rheumatoid arthritis, its 
association with AITD is still uncertain.1 Table 1 
delineates a number of studies, where an association 
of AITD with vitamin D deficiency was either 
confirmed or refuted.  Certain polymorphisms in the 
vitamin D receptor gene (mainly the BsmI or TaqI) 
were noted to confer an increased AITD risk.28 
Moreover, a recent trial has demonstrated that 
vitamin D supplementation causes significant TPO-
Ab titre reductions.29  
6. Infections
Several infections have been implicated in the
development of AITD in genetically susceptible 
individuals including Yersinia enterocolitica, 
Hepatitis C virus, Coxsackie B virus, retroviruses, 
Borrelia Burgdorferi and Helicobacter pylori 
infection, particularly the cytotoxin-associated gene 
A strain.  Infections may trigger AITD by several 
mechanisms, some of which may include release of 
sequestered antigens on cell apoptosis/destruction, 
molecular mimicry (an epitope on bacterium/virus 
is recognized as self), cryptic epitope exposure and 
activation of resident T-cells through inflammation 
and cytokine secretion.30  
Table 1.  Association of Vitamin D deficiency with 
AITD in some clinical studies. 
Study 
AITD associated with 
Vitamin D deficiency? 
Effraimidis G et al. 
201243 
NO 
D'Aurizio F et al. 201544 NO 
Yasmeh J et al. 201645 NO 
Kivity S et al. 201146 YES 
Bozkurt NC et al. 
201347 
YES 
Wang J et al. 2015 (A 
meta-analysis)48
YES 
7. Seasonality
Hamilton et al investigated the effect of month
of birth and seasonality on AITD onset in northern 
European Caucasian and United Kingdom 
populations and found no impact of month of birth 
on GD development.  However, slightly higher 
birth rates in autumn were detected in HT females 
from the OXAGEN AITD Caucasian family 
collection.31 A previous Greek study showed that 
male GD birth rates peaked in winter, while females 
with GD had two birth peaks: spring and autumn.  
Conversely, HT female birth rates peaked in winter, 
while males with HT were mostly born in winter 
and summer. In the general population births 
peaked in summer for both males and females. 
Therefore, they argued that both GD and HT have a 
similar aetiology as T1D and multiple sclerosis i.e. 
seasonal bacterial/viral infections during the 
perinatal period may be the initial trigger, as most 
births of AITD individuals peaked in winter and 
autumn.32   
8. Drug Therapy
Several drugs may induce TAI including
interferon-α, interleukin-2, campath-1H and highly 
active antiretroviral therapy. Instead of causing de 
novo TAI, lithium and amiodarone (an iodine rich 
drug) appear to be key risk factors for the 
development of hypothyroidism in patients with 
pre-existing TAI. Amiodarone’s iodine load is also 
responsible for inducing the onset of previously 
subclinical GD, resulting in autoimmune 
thyrotoxicosis.10   
Oestrogen use (as the oral contraceptive pill 
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[OCP] or hormone replacement therapy [HRT]) was 
found to have varied effects on TAI in different 
studies. It was found to be negatively correlated to 
TPO-Abs and was associated with a lower risk of 
subclinical or overt hyperthyroidism (but not 
autoimmune hypothyroidism) in a cross-sectional 
analysis of the Amsterdam AITD cohort.33 In a 
Danish population-based cross-sectional study, only 
the use of HRT was associated with a lower 
occurrence of Tg-Abs (but not of TPO-Abs),13 
while no difference in thyroid antibody frequency 
was noted in post-menopausal women with or 
without HRT in a different study.34 Furthermore, 
oestrogen use was found to have no correlation with 
thyroid antibodies in a Japanese-Brazilian 
population-based study.35   
9. Radiation exposure
AITD is connected to therapeutic radiation
including radioactive iodine, as well as occupational 
and environmental radiation exposure. Increased 
AITD was initially seen in atomic bomb survivors 
in Japan and following the radioactive fallout in 
Chernobyl.36
10. Toxic chemicals
Polyaromatic hydrocarbons including 
polychlorinated biphenyls (PCB) and 
polyhalogenated biphenyls (PBB) are organic 
compounds found in water and air and are made 
from coal. An increase in antimicrosomal and Tg-
Abs together with a higher occurrence of 
hypothyroidism was noted in workers exposed to 
PBBs.37 A higher prevalence of thyroid antibodies 
and an increased thyroid volume was also noted in 
Slovakian workers exposed to PCB.38 Bisphenol A, 
perfluorinated chemicals, phthalates,30, 36 solvents, 
metals, other anthropogenic compounds and 
petrochemical complex-related pollution have also 
been associated with AITD. Chemical toxins might 
trigger AITD by disrupting the immune system 
and/or interfering with thyroid function or by 
altering the thyroglobulin structure increasing its 
immunogenicity.39   
11. Iodine
Autoimmune hypothyroidism and thyroid
antibodies tend to be more prevalent in iodine 
replete areas and in individuals with excessive 
iodine intake or following iodization programmes.1 
In a Danish study, TPO and Tg-Abs became more 
prevalent after iodine fortification of salt, especially 
in young women and at low concentrations of 
antibody.40 A higher prevalence of hyperthyroidism, 
especially in young individuals, was also noted in 
two areas of Denmark with moderate and mild 
iodine deficiency after cautious iodine fortification 
of salt.41 However, a large Italian study observed an 
absence of an association between iodine 
fortification and HT or iodine induced 
hyperthyroidism.42   
Table 2.  The natural history of progression of AITD.1
Stage Clinical Thyroid status Thyroid Abs Other changes 
1 Euthyroid Absent 
Evidence of immune activation including changes 
in chemokines, vascular adhesion molecules, GFs 
cytokines and tissue remodelling factors 
2 Euthyroid Present TSH starts getting deranged 
3 
Subclinical 
hypo/hyperthyroidism 
Present 
Duration longer for subclinical hypothyroidism 
than subclinical hyperthyroidism 
4 
Overt 
hypo/hyperthyroidism 
Present 
Abs – antibodies; GFs- growth factors; TSH- thyroid stimulating hormone. 
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Natural history of AITD 
The natural history of AITD involves four 
stages which are delineated in table 2. In a 
prospective study, progression to overt autoimmune 
hypothyroidism from euthyroidism took several 
years unlike the development of overt autoimmune 
hyperthyroidism which occurred after a few 
months.11   
Conclusion 
In conclusion, several environmental factors can 
affect progression to TAI.  While some factors 
appear to predispose to both GD and HT, others 
may predispose to GD but protect against HT.1 
Preventive measures might involve public health 
interventions such as monitoring iodine intake and 
providing education against smoking. Promoting 
alcohol consumption, which has its own adverse 
effects, is unlikely to be feasible, while stress 
avoidance is not always pragmatic. Whether 
selenium and vitamin D supplementation can 
improve or protect against TAI is still indeterminate 
and requires further research. Other risk factors 
such as seasonality of birth, age and gender are non-
modifiable, while avoidance of pregnancy is non-
realistic.6 
References 
1. Effraimidis G, Wiersinga WM. Mechanisms in
endocrinology: autoimmune thyroid disease: old and new
players. Eur J Endocrinol. 2014;170(6):R241-52.
2. McLeod DS, Cooper DS. The incidence and prevalence
of thyroid autoimmunity. Endocrine. 2012;42(2):252-65.
3. McGrogan A, Seaman HE, Wright JW, de Vries CS. The
incidence of autoimmune thyroid disease: a systematic
review of the literature. Clin Endocrinol (Oxf).
2008;69(5):687-96.
4. Hollowell JG, Staehling NW, Flanders WD, Hannon
WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4),
and thyroid antibodies in the United States population
(1988 to 1994): National Health and Nutrition
Examination Survey (NHANES III). J Clin Endocrinol
Metab. 2002;87(2):489-99.
5. Brix TH, Kyvik KO, Christensen K, Hegedus L.
Evidence for a major role of heredity in Graves' disease:
a population-based study of two Danish twin cohorts. J
Clin Endocrinol Metab. 2001;86(2):930-4.
6. Wiersinga WM. Clinical Relevance of Environmental
Factors in the Pathogenesis of Autoimmune Thyroid
Disease. Endocrinol Metab (Seoul). 2016;31(2):213-22.
7. Hansen PS, Brix TH, Iachine I, Kyvik KO, Hegedus L.
The relative importance of genetic and environmental
effects for the early stages of thyroid autoimmunity: a
study of healthy Danish twins. Eur J Endocrinol.
2006;154(1):29-38.
8. Vanderpump MP. The epidemiology of thyroid disease.
Br Med Bull. 2011;99:39-51.
9. Gleicher N, Barad DH. Gender as risk factor for
autoimmune diseases. J Autoimmun. 2007;28(1):1-6.
10. Tanda ML, Piantanida E, Lai A, Lombardi V, Dalle
Mule I, Liparulo L, et al. Thyroid autoimmunity and
environment. Horm Metab Res. 2009;41(6):436-42.
11. Effraimidis G, Strieder TG, Tijssen JG, Wiersinga WM.
Natural history of the transition from euthyroidism to
overt autoimmune hypo- or hyperthyroidism: a
prospective study. Eur J Endocrinol. 2011;164(1):107-
13.
12. Lepez T, Vandewoestyne M, Hussain S, Van
Nieuwerburgh F, Poppe K, Velkeniers B, et al. Fetal
microchimeric cells in blood of women with an
autoimmune thyroid disease. PLoS One.
2011;6(12):e29646.
13. Bulow Pedersen I, Laurberg P, Knudsen N, Jorgensen T,
Perrild H, Ovesen L, et al. Lack of association between
thyroid autoantibodies and parity in a population study
argues against microchimerism as a trigger of thyroid
autoimmunity. Eur J Endocrinol. 2006;154(1):39-45.
14. Bjergved L, Carle A, Jorgensen T, Perrild H, Laurberg P,
Krejbjerg A, et al. Parity and 11-Year Serum Thyrotropin
and Thyroid Autoantibody Change: A Longitudinal
Population-Based Study. Thyroid. 2016;26(2):203-11.
15. Vestergaard P. Smoking and thyroid disorders--a meta-
analysis. Eur J Endocrinol. 2002;146(2):153-61.
16. Pedersen IB, Laurberg P, Knudsen N, Jorgensen T,
Perrild H, Ovesen L, et al. Smoking is negatively
associated with the presence of thyroglobulin
autoantibody and to a lesser degree with thyroid
peroxidase autoantibody in serum: a population study.
Eur J Endocrinol. 2008;158(3):367-73.
17. Effraimidis G, Tijssen JG, Wiersinga WM.
Discontinuation of smoking increases the risk for
developing thyroid peroxidase antibodies and/or
thyroglobulin antibodies: a prospective study. J Clin
Endocrinol Metab. 2009;94(4):1324-8.
18. Carle A, Bulow Pedersen I, Knudsen N, Perrild H,
Ovesen L, Banke Rasmussen L, et al. Smoking cessation
is followed by a sharp but transient rise in the incidence
of overt autoimmune hypothyroidism - a population-
based, case-control study. Clin Endocrinol (Oxf).
2012;77(5):764-72.
19. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L,
Rasmussen LB, et al. Moderate alcohol consumption
may protect against overt autoimmune hypothyroidism: a
population-based case-control study. Eur J Endocrinol.
2012;167(4):483-90.
20. Carlé A, Bülow Pedersen I, Knudsen N, Perrild H,
Ovesen L, Rasmussen LB, et al. Graves' hyperthyroidism
and moderate alcohol consumption: evidence for disease
prevention. Clin Endocrinol (Oxf). 2013;79(1):111-9.
21. Effraimidis G, Tijssen JG, Brosschot JF, Wiersinga WM.
Involvement of stress in the pathogenesis of autoimmune
thyroid disease: a prospective study.
Psychoneuroendocrinology. 2012;37(8):1191-8.
22. Winsa B, Adami HO, Bergstrom R, Gamstedt A,
Dahlberg PA, Adamson U, et al. Stressful life events and
Graves' disease. Lancet. 1991;338(8781):1475-9.
30
Editorial OrgOdReReview Article 
 Malta Medical Journal     Volume 30  Issue 01 2018 
23. Matos-Santos A, Nobre EL, Costa JG, Nogueira PJ,
Macedo A, Galvao-Teles A, et al. Relationship between
the number and impact of stressful life events and the
onset of Graves' disease and toxic nodular goitre. Clin
Endocrinol (Oxf). 2001;55(1):15-9.
24. Fukao A, Takamatsu J, Murakami Y, Sakane S,
Miyauchi A, Kuma K, et al. The relationship of
psychological factors to the prognosis of
hyperthyroidism in antithyroid drug-treated patients with
Graves' disease. Clin Endocrinol (Oxf). 2003;58(5):550-
5.
25. Wu Q, Rayman MP, Lv H, Schomburg L, Cui B, Gao C,
et al. Low Population Selenium Status Is Associated
With Increased Prevalence of Thyroid Disease. J Clin
Endocrinol Metab. 2015;100(11):4037-47.
26. Bulow Pedersen I, Knudsen N, Carle A, Schomburg L,
Kohrle J, Jorgensen T, et al. Serum selenium is low in
newly diagnosed Graves' disease: a population-based
study. Clin Endocrinol (Oxf). 2013;79(4):584-90.
27. van Zuuren EJ, Albusta AY, Fedorowicz Z, Carter B, Pijl
H. Selenium supplementation for Hashimoto's
thyroiditis. Cochrane Database Syst Rev.
2013(6):Cd010223.
28. Feng M, Li H, Chen SF, Li WF, Zhang FB.
Polymorphisms in the vitamin D receptor gene and risk
of autoimmune thyroid diseases: a meta-analysis.
Endocrine. 2013;43(2):318-26.
29. Chaudhary S, Dutta D, Kumar M, Saha S, Mondal SA,
Kumar A, et al. Vitamin D supplementation reduces
thyroid peroxidase antibody levels in patients with
autoimmune thyroid disease: An open-labeled
randomized controlled trial. Indian J Endocrinol Metab.
2016;20(3):391-8.
30. Eschler DC, Hasham A, Tomer Y. Cutting edge: the
etiology of autoimmune thyroid diseases. Clin Rev
Allergy Immunol. 2011;41(2):190-7.
31. Hamilton A, Newby PR, Carr-Smith JD, Disanto G,
Allahabadia A, Armitage M, et al. Impact of month of
birth on the development of autoimmune thyroid disease
in the United Kingdom and Europe. J Clin Endocrinol
Metab. 2014;99(8):E1459-65.
32. Krassas GE, Tziomalos K, Pontikides N, Lewy H, Laron
Z. Seasonality of month of birth of patients with Graves'
and Hashimoto's diseases differ from that in the general
population. Eur J Endocrinol. 2007;156(6):631-6.
33. Strieder TG, Prummel MF, Tijssen JG, Endert E,
Wiersinga WM. Risk factors for and prevalence of
thyroid disorders in a cross-sectional study among
healthy female relatives of patients with autoimmune
thyroid disease. Clin Endocrinol (Oxf). 2003;59(3):396-
401.
34. Massoudi MS, Meilahn EN, Orchard TJ, Foley TP, Jr.,
Kuller LH, Costantino JP, et al. Prevalence of thyroid
antibodies among healthy middle-aged women. Findings
from the thyroid study in healthy women. Ann
Epidemiol. 1995;5(3):229-33.
35. Sgarbi JA, Kasamatsu TS, Matsumura LK, Maciel RM.
Parity is not related to autoimmune thyroid disease in a
population-based study of Japanese-Brazilians. Thyroid.
2010;20(10):1151-6.
36. Brent GA. Environmental exposures and autoimmune
thyroid disease. Thyroid. 2010;20(7):755-61.
37. Bahn AK, Mills JL, Snyder PJ, Gann PH, Houten L,
Bialik O, et al. Hypothyroidism in workers exposed to
polybrominated biphenyls. N Engl J Med.
1980;302(1):31-3.
38. Langer P, Tajtakova M, Fodor G, Kocan A, Bohov P,
Michalek J, et al. Increased thyroid volume and
prevalence of thyroid disorders in an area heavily
polluted by polychlorinated biphenyls. Eur J Endocrinol.
1998;139(4):402-9.
39. Benvenga S, Antonelli A, Vita R. Thyroid nodules and
thyroid autoimmunity in the context of environmental
pollution. Rev Endocr Metab Disord. 2015;16(4):319-40.
40. Pedersen IB, Knudsen N, Carle A, Vejbjerg P, Jorgensen
T, Perrild H, et al. A cautious iodization programme
bringing iodine intake to a low recommended level is
associated with an increase in the prevalence of thyroid
autoantibodies in the population. Clin Endocrinol (Oxf).
2011;75(1):120-6.
41. Bulow Pedersen I, Laurberg P, Knudsen N, Jorgensen T,
Perrild H, Ovesen L, et al. Increase in incidence of
hyperthyroidism predominantly occurs in young people
after iodine fortification of salt in Denmark. J Clin
Endocrinol Metab. 2006;91(10):3830-4.
42. Tammaro A, Pigliacelli F, Fumarola A, Persechino S.
Trends of thyroid function and autoimmunity to 5 years
after the introduction of mandatory iodization in Italy.
Eur Ann Allergy Clin Immunol. 2016;48(3):77-81.
43. Effraimidis G, Badenhoop K, Tijssen JG, Wiersinga
WM. Vitamin D deficiency is not associated with early
stages of thyroid autoimmunity. Eur J Endocrinol.
2012;167(1):43-8.
44. D'Aurizio F, Villalta D, Metus P, Doretto P, Tozzoli R.
Is vitamin D a player or not in the pathophysiology of
autoimmune thyroid diseases? Autoimmun Rev.
2015;14(5):363-9.
45. Yasmeh J, Farpour F, Rizzo V, Kheradnam S, Sachmechi
I. HASHIMOTO'S THYROIDITIS NOT ASSOCIATED
WITH VITAMIN-D DEFICIENCY. Endocr Pract. 2016.
46. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy
EV, Danko K, et al. Vitamin D and autoimmune thyroid
diseases. Cell Mol Immunol. 2011;8(3):243-7.
47. Bozkurt NC, Karbek B, Ucan B, Sahin M, Cakal E,
Ozbek M, et al. The association between severity of
vitamin D deficiency and Hashimoto's thyroiditis.
Endocr Pract. 2013;19(3):479-84.
48. Wang J, Lv S, Chen G, Gao C, He J, Zhong H, et al.
Meta-analysis of the association between vitamin D and
autoimmune thyroid disease. Nutrients. 2015;7(4):2485-
98.
31
